In the past decade, single-cell technologies have proliferated and improved from their
technically challenging beginnings to become common laboratory methods capable of …

Alzheimer's disease (AD) is prevalent throughout the world and is the leading cause of
dementia in older individuals (aged≥ 65 years). To gain a deeper understanding of the …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

The ɛ4 allele of the apolipoprotein E gene (APOE), which translates to the APOE4 isoform,
is the strongest genetic risk factor for late-onset Alzheimer disease (AD). Within the CNS …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …